Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

DA Davidson lowered the firm’s price target on Vertex (VERX) to $50 from $55 and keeps a Buy rating on the shares as part of a broader research note updating estimates within the firm’s ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $462.00. The company’s shares closed yesterday ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

Tyler Colp is a games writer at Polygon specializing in criticism and reporting about extraordinary players and communities. I spent 20 hours playing Assassin’s Creed Shadows before I spent my ...

VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of thePhase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study ...

Vertex Trading Down 1.2 % NASDAQ VERX opened at $35.71 on Monday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.04 and a current ratio of 1.04. Vertex, Inc. has a one year low ...

Previously, Veo 2 was only available to a select group of Vertex AI users ... clicking the down arrow next to the Gemini Advanced logo and selecting Veo 2 from the list of models.

The vibe coding era is here. Will you survive it? It's a question software engineers are increasingly asking as AI automates more of their work. Software experts suggested embracing AI tools ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...